| Dr Michael Spellman Harris, MD | |
|
1330 N Beckley Ave, Dallas, TX 75203-1271 | |
| (214) 941-3933 | |
| (214) 941-2979 |
| Full Name | Dr Michael Spellman Harris |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 1330 N Beckley Ave, Dallas, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063483386 | NPI | - | NPPES |
| 099615901 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | D3255 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Spellman Harris, MD 1330 N Beckley Ave, Dallas, TX 75203-1277 Ph: (214) 941-3933 | Dr Michael Spellman Harris, MD 1330 N Beckley Ave, Dallas, TX 75203-1271 Ph: (214) 941-3933 |
News Archive
Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.
Janardan Pandey, Ph.D., an immunogeneticist specializing in immunoglobulin GM genes at the Medical University of South Carolina, helped monitor for immune responses that could limit the effectiveness of the broadly neutralizing antibody VRC01 in a phase 1 trial of that antibody in HIV-infected individuals led by a team at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Bayer today announced positive data on its investigational compound copanlisib, an intravenous pan-Class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against PI3K-α and PI3K-δ isoforms.
Endocrine disrupters are not the only worrying chemicals that ordinary consumers are exposed to in everyday life. Also nanoparticles of silver, found in e.g. dietary supplements, cosmetics and food packaging, now worry scientists.
› Verified 6 days ago
Dr. Joanna Saade, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2020 | |
Dr. Julie Linden Soto, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1703 N Beckley Ave, Dallas, TX 75203 Phone: 214-987-2875 Fax: 214-946-9877 | |
Miss Vanessa Ortiz-medina, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2020 | |
Dr. Deborah I Friedman, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Boulevard, Dallas, TX 75390 Phone: 214-645-0624 Fax: 214-645-0078 | |
Faisal E Haq, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2801 Lemmon Ave Ste 400, Dallas, TX 75204 Phone: 214-754-0000 Fax: 214-379-1849 | |
Gary Pesicka, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2020 | |
Phillip Alan Tenzel, M.D. Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75284 Phone: 214-645-2020 |